How to use this reference
Each presenting complaint below is organized into three escalating stacks of actives, built strictly from the ReVitaCore catalog. Tiers add distinct mechanisms rather than simply more product — Beginner addresses the most direct, fastest-acting pathway; Advanced layers in a second physiological system; Pro provides comprehensive mechanistic coverage for complex or treatment-resistant presentations.
Where two GLP-class actives appear in the same tier, they are presented as either/or options for the incretin backbone, never as a combined stack, unless otherwise noted. Several complaints (vasomotor symptoms, PMS/PMDD, PCOS, vaginal atrophy) are specific to female physiology and have no male-document equivalent; others share an underlying mechanism with the male reference but are reframed around the estrogen-decline or cyclical-hormone context relevant to female patients.
Fatigue / Low Energy
Direct mitochondrial bioenergetic support. Fatigue is the single most prevalent symptom reported across perimenopausal and menopausal cohorts, often outranking vasomotor symptoms in frequency.
-
NAD+
Central mitochondrial cofactor for the electron transport chain and a substrate for sirtuin and PARP enzymes; restores cellular ATP production and supports DNA repair. The single most patient-perceivable energy intervention in the catalog.
-
MOTS-c
Mitochondrial-derived peptide that improves metabolic flexibility, insulin sensitivity, and exercise capacity at the cellular level; complements NAD+ by upregulating mitochondrial biogenesis.
Patient feels a measurable energy lift within the first week or two — both address the root substrate of fatigue rather than masking symptoms.
-
NAD+
Central mitochondrial cofactor for the electron transport chain; restores cellular ATP production.
-
MOTS-c
Mitochondrial-derived peptide; upregulates mitochondrial biogenesis.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog paired with a selective GH secretagogue; restores youthful nocturnal GH pulses, driving deep-sleep recovery and morning energy levels. GH-axis decline accelerates through perimenopause independent of ovarian hormone status.
-
DSIP
Directly enhances delta-wave (slow-wave) sleep architecture; addresses the “slept eight hours but woke up exhausted” patient where sleep depth, not quantity, is the issue — a pattern frequently disrupted by nocturnal vasomotor symptoms.
Hits daytime energy substrate and the overnight recovery engine together, particularly relevant where night sweats are already fragmenting sleep architecture.
-
NAD+
Central mitochondrial cofactor for cellular ATP production and DNA repair.
-
MOTS-c
Mitochondrial-derived peptide for metabolic flexibility and biogenesis.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog with selective GH secretagogue; restores nocturnal GH pulses.
-
DSIP
Enhances delta-wave sleep architecture.
-
N-Acetyl Semax
Neuropeptide that modulates BDNF and dopamine signaling; addresses the cognitive/motivational component of fatigue where mental drive, not physical energy, is the dominant deficit.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator; supports HPA axis recovery where adrenal dysregulation underlies fatigue, common during the perimenopausal cortisol/estrogen interplay.
-
SS-31
Mitochondria-targeted peptide that stabilizes the inner mitochondrial membrane and reduces reactive oxygen species; indicated for deep mitochondrial dysfunction (post-viral, chemotherapy-related fatigue).
-
Methylene Blue
Alternative electron carrier in the mitochondrial chain; bypasses dysfunctional Complex I/III to maintain ATP output.
Contraindicated with SSRIs/SNRIs (serotonin syndrome risk).
Covers mitochondrial substrate and advanced rescue, GH-axis recovery, sleep architecture, neurological drive, and adrenal/HPA support.
Weight Gain / Difficulty Losing Weight
Direct appetite and glycemic control via the incretin pathway. Both actives address appetite, satiety, and glycemic control without requiring complex multi-system intervention; particularly relevant given the metabolic shift toward visceral fat accumulation that follows declining estrogen.
The two GLP-class actives below are either/or options, not a combined stack. Choose one based on patient profile; they are not used together.
-
Semaglutide (GLP-1S)Option A
GLP-1 receptor agonist; suppresses appetite via CNS pathways, slows gastric emptying, improves insulin sensitivity. Typical results of 12–15% total body weight loss. Preferred for cost-sensitive or moderate-BMI patients.
-
Tirzepatide (GLP-2T)Option B
Dual GLP-1/GIP receptor agonist; greater weight loss than semaglutide alone (typically 18–22% total body weight). Preferred for higher-BMI patients or metabolic syndrome.
The two GLP-class actives below are either/or options, not a combined stack. Choose one as the incretin backbone; the remaining actives stack on top of it.
-
Tirzepatide (GLP-2T)Option A — backbone
Dual GLP-1/GIP receptor agonist; produces 18–22% total body weight loss. Preferred for higher-BMI patients or metabolic syndrome.
-
Retatrutide (GLP-3R)Option B — backbone
Triple agonist (GLP-1, GIP, glucagon); the most powerful weight-loss active in development, with phase 2 data showing 24%+ total body weight loss. Glucagon component drives hepatic fat oxidation and resting energy expenditure.
-
AOD9604
Modified GH fragment (176–191) that selectively stimulates lipolysis and inhibits lipogenesis without affecting blood glucose or IGF-1; targets fat-specific loss without muscle-catabolic risk.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog with selective GH secretagogue; preserves and builds lean muscle mass during weight loss, preventing the sarcopenic shift that compounds with the menopausal decline in muscle mass.
-
MOTS-c
Mitochondrial-derived peptide; addresses the metabolic adaptation (“starvation mode”) that stalls weight loss after initial progress.
Prevents the two failure modes of basic GLP-1 weight loss — muscle wasting and metabolic slowdown — both of which compound the menopausal shift in body composition.
Retatrutide is listed as the single incretin backbone at this tier. It is not stacked with Semaglutide or Tirzepatide — only one GLP-class active is used at a time.
-
Retatrutide (GLP-3R)incretin backbone
Triple agonist (GLP-1, GIP, glucagon); the most powerful weight-loss active in development, with 24%+ total body weight loss in phase 2 data.
-
Cagrilintide
Long-acting amylin analog; suppresses appetite via a non-GLP-1 pathway, slows gastric emptying, produces additive weight loss alongside GLP-1 agonists.
-
AOD9604
Modified GH fragment; selective lipolysis without affecting blood glucose or IGF-1.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog with selective GH secretagogue; muscle preservation during weight loss.
-
5-Amino-1MQ
Selective NNMT inhibitor; increases cellular NAD+ availability in adipocytes, reduces fat storage capacity, supports lean mass via a fundamentally different mechanism.
-
MOTS-c
Mitochondrial-derived peptide; addresses metabolic adaptation that stalls weight loss.
-
SLU-PP-332
ERR agonist and exercise mimetic; upregulates mitochondrial biogenesis and fatty acid oxidation, producing exercise-like metabolic adaptations without the workout.
-
Tesofensine
Dopamine/norepinephrine/serotonin reuptake inhibitor; appetite suppression and increased energy expenditure via central monoamine pathways, separate from incretin mechanisms.
Stimulant-class; screen for cardiovascular risk.
Covers central appetite suppression via incretin and amylin pathways, monoamine-mediated appetite control, targeted lipolysis, muscle preservation, enzymatic fat-storage inhibition, and mitochondrial/exercise-mimetic enhancement.
Brain Fog / Poor Concentration & Memory
Direct cognitive enhancement via neuropeptide modulation. Memory complaints and difficulty concentrating are reported by over 90% of women in large perimenopausal cohorts, frequently exceeding vasomotor symptoms in both prevalence and patient-reported burden.
-
N-Acetyl Semax
Neuropeptide derived from ACTH; upregulates BDNF, modulates dopamine and serotonin systems, enhances focus, mental energy, and cognitive processing speed.
-
N-Acetyl Selank
Anxiolytic neuropeptide that modulates GABA and serotonin systems; reduces the cognitive interference from stress and anxiety while preserving alertness.
Targets the two most common subjective drivers of brain fog — attentional/motivational deficit and anxious mental noise — both of which intensify during the perimenopausal transition.
-
N-Acetyl Semax
Upregulates BDNF; enhances focus, mental energy, and cognitive processing speed.
-
N-Acetyl Selank
Anxiolytic neuropeptide reducing cognitive interference from stress and anxiety.
-
NAD+
Central mitochondrial cofactor; the brain is the most metabolically demanding organ in the body, and NAD+ depletion directly impairs neuronal ATP production.
-
DIHEXA
Angiotensin IV analog and the most potent neurotrophic compound currently known; promotes synaptogenesis and dendritic spine formation.
-
DSIP
Enhances delta-wave sleep architecture; the glymphatic system clears beta-amyloid and metabolic waste during deep sleep, frequently disrupted by nocturnal vasomotor symptoms.
Adds the cellular energy substrate, structural neurotrophic layer, and overnight cognitive recovery system.
-
N-Acetyl Semax
Upregulates BDNF and dopamine signaling for focus and processing speed.
-
N-Acetyl Selank
Anxiolytic neuropeptide reducing cognitive interference from stress.
-
NAD+
Mitochondrial cofactor for neuronal ATP production.
-
DIHEXA
Potent neurotrophic compound promoting synaptogenesis and dendritic spine formation.
-
DSIP
Slow-wave sleep architecture for glymphatic clearance.
-
PE-22-28
Synthetic spadin analog and TREK-1 potassium channel blocker; rapid antidepressant-like and neuroprotective effects, addressing the depressive/anhedonic overlap with cognitive complaints.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator; supports HPA axis recovery where cortisol dysregulation drives hippocampal dysfunction.
-
Pinealonbioregulator
Pineal/CNS tissue-specific bioregulator supporting neuronal function and circadian regulation.
-
Methylene Blue
Alternative mitochondrial electron carrier and nitric oxide modulator; bypasses dysfunctional complexes to maintain neuronal ATP output.
Contraindicated with SSRIs/SNRIs.
Covers neurotransmitter modulation, cellular bioenergetics, neurotrophic/structural enhancement, sleep-driven glymphatic clearance, mood overlap, and HPA axis recovery.
Hot Flashes / Night Sweats (Vasomotor Symptoms)
Thermoregulatory and circadian support, targeting the hypothalamic mechanism underlying vasomotor instability. Affects up to 75% of postmenopausal women and is the most recognized, if not always the most burdensome, menopausal complaint.
-
Epithalon
Pineal-derived peptide that regulates melatonin production and circadian rhythm; supports the hypothalamic thermoregulatory centers implicated in vasomotor instability and helps restore the disrupted sleep-wake cycle that accompanies frequent night sweats.
-
Oxytocin
Promotes parasympathetic tone and reduces sympathetic surge activity; vasomotor flushes are driven by an exaggerated sympathetic response to small core-temperature changes, and parasympathetic support can blunt the frequency and intensity of episodes.
Addresses the circadian and autonomic regulation underlying flush frequency without hormonal intervention, suitable as a first-line option or an adjunct for patients not on or not candidates for estrogen therapy.
-
Epithalon
Pineal-derived peptide supporting hypothalamic thermoregulation and circadian rhythm.
-
Oxytocin
Promotes parasympathetic tone, reducing sympathetic flush triggers.
-
Pinealonbioregulator
Pineal/CNS tissue-specific bioregulator supporting hypothalamic and thermoregulatory center function at the cellular level.
-
DSIP
Directly enhances delta-wave sleep architecture; restores sleep continuity that is otherwise fragmented by nocturnal vasomotor episodes.
-
NAD+
Mitochondrial cofactor supporting the autonomic nervous system's energy demands and overall thermoregulatory resilience.
Layers cellular-level hypothalamic support, sleep restoration, and autonomic energy substrate onto the circadian and parasympathetic foundation.
-
Epithalon
Pineal-derived peptide supporting hypothalamic thermoregulation.
-
Oxytocin
Parasympathetic tone supporting reduced flush frequency.
-
Pinealonbioregulator
Hypothalamic and thermoregulatory bioregulator support.
-
DSIP
Restores sleep continuity disrupted by night sweats.
-
NAD+
Mitochondrial and autonomic energy substrate.
-
N-Acetyl Selank
Anxiolytic neuropeptide reducing the anticipatory anxiety and stress reactivity that can intensify flush frequency and severity in some patients.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator; supports the HPA axis, which interacts closely with hypothalamic thermoregulatory control during the menopausal transition.
Provides comprehensive coverage of the circadian, autonomic, cellular, sleep, anxiolytic, and HPA-axis contributors to vasomotor symptom frequency and severity.
Mood Changes / Irritability / Anxiety (Perimenopausal)
Direct neuropeptide modulation of mood and anxiety. Irritability and tension/nervousness rank among the most prevalent perimenopausal symptoms, often exceeding 90% prevalence in tracked cohorts, and respond robustly to hormone-sensitive interventions.
-
N-Acetyl Selank
Anxiolytic neuropeptide that modulates GABA and serotonin systems; reduces irritability, anxious arousal, and stress reactivity without sedation or cognitive blunting.
-
PE-22-28
Synthetic spadin analog and TREK-1 potassium channel blocker; produces rapid antidepressant-like effects without the delayed onset of SSRIs, and avoids the side-effect profile that often complicates antidepressant use during the menopausal transition.
Covers the two most common mood presentations during perimenopause — anxious irritability and depressive flatness — with rapid onset rather than the weeks-long lag of conventional antidepressants.
-
N-Acetyl Selank
Anxiolytic neuropeptide reducing irritability and stress reactivity.
-
PE-22-28
Rapid antidepressant-like effects without delayed SSRI onset.
-
N-Acetyl Semax
Neuropeptide upregulating BDNF and dopamine signaling; restores motivational and drive deficits that frequently accompany the “profound low mood” pattern reported in perimenopausal cohorts.
-
Oxytocin
Supports emotional regulation and parasympathetic tone; the decline in oxytocin signaling alongside estrogen during the menopausal transition is increasingly implicated in mood instability.
Adds dopaminergic drive restoration and direct oxytocinergic support, addressing the broader emotional-regulation shift that accompanies declining estrogen.
-
N-Acetyl Selank
Anxiolytic neuropeptide modulating GABA and serotonin systems.
-
N-Acetyl Semax
Upregulates BDNF and dopamine signaling for motivational restoration.
-
PE-22-28
Rapid antidepressant-like effects without delayed onset of SSRIs.
-
Oxytocin
Supports emotional regulation and parasympathetic tone.
-
NAD+
Mitochondrial cofactor addressing bioenergetic dysfunction implicated in depression.
-
DIHEXA
Potent neurotrophic compound promoting synaptogenesis, addressing structural neuroplasticity deficits that underlie persistent mood disturbance.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator; supports HPA axis recovery where chronic stress has dysregulated cortisol and depleted adrenal reserve.
-
DSIP
Enhances delta-wave sleep architecture; sleep disruption is both a cause and consequence of mood instability, compounded by nocturnal vasomotor symptoms.
-
Methylene Blue
Alternative mitochondrial electron carrier with documented antidepressant research; addresses bioenergetic and oxidative dysfunction pathways.
Contraindicated with SSRIs/SNRIs.
Covers neurotransmitter modulation, rapid antidepressant pathway, oxytocinergic and hormonal-adjacent mood substrate, neurotrophic plasticity, HPA axis recovery, sleep architecture, and mitochondrial bioenergetics.
Low Libido
Direct central libido pathway. The goal is fast, perceivable results with minimal complexity — both actives work centrally and don't require labs or hormonal titration. Loss of libido is reported by more than 90% of women in some menopausal cohorts, frequently as the most severe symptom overall.
-
PT-141 (Bremelanotide)
Melanocortin-4 receptor agonist; the only FDA-approved compound for hypoactive sexual desire disorder in premenopausal women, and broadly effective off-label across the menopausal transition. Directly increases sexual desire and arousal via CNS pathway, independent of estrogen status.
-
Oxytocin
Enhances arousal, emotional connection, and orgasm intensity. Pairs synergistically with PT-141 (desire + bonding), and addresses the relational/emotional dimension of libido that is frequently as important as the physiological one.
Patient feels something on day one. Both work centrally and independently of estrogen or testosterone status, making them appropriate first-line options regardless of menopausal stage or hormone therapy candidacy.
-
PT-141 (Bremelanotide)
Melanocortin-4 receptor agonist; FDA-approved for hypoactive sexual desire disorder, effective across the menopausal transition.
-
Oxytocin
Enhances arousal, emotional connection, and orgasm intensity.
-
Kisspeptin
Upstream regulator of the hypothalamic-pituitary-gonadal axis with direct effects on limbic brain regions involved in sexual behavior, independent of its role in reproductive hormone signaling.
-
NAD+
Mitochondrial cofactor critical to cellular energy production and endothelial/nitric oxide signaling; addresses the “tired libido” patient where energy deficit, not desire deficit, is the limiting factor.
Layers in central limbic signaling and the energy/vascular substrate needed for libido to register, without introducing exogenous hormone.
-
PT-141 (Bremelanotide)
Melanocortin-4 receptor agonist; FDA-approved for hypoactive sexual desire disorder.
-
Oxytocin
Enhances arousal, emotional connection, and orgasm intensity.
-
Kisspeptin
Upstream HPG-axis regulator with direct limbic effects on sexual behavior.
-
NAD+
Mitochondrial cofactor supporting cellular energy and endothelial nitric oxide signaling.
-
Tesofensine
Dopamine, norepinephrine, and serotonin reuptake inhibitor; restores the dopaminergic “desire and motivation” axis often blunted by chronic stress or anhedonia-driven libido loss.
Stimulant-class; screen for cardiovascular risk. -
Vesilutebioregulator
Bladder and urogenital tissue-specific bioregulator; supports the vascular and tissue substrate of the urogenital region relevant to arousal physiology.
-
Methylene Blue
Mitochondrial electron transport chain enhancer and nitric oxide pathway modulator; addresses the vascular and cellular-energy components of arousal physiology.
Contraindicated with SSRIs/SNRIs (serotonin syndrome risk).
Covers central desire, limbic/hormonal-adjacent signaling, tissue-level urogenital, vascular, and metabolic mechanisms simultaneously — the comprehensive workup for a longevity-clinic patient.
Sleep Disturbances / Insomnia
Direct slow-wave sleep architecture and circadian regulation. Both actives target the two foundational sleep systems — depth and timing — frequently disrupted by nocturnal vasomotor symptoms during the menopausal transition.
-
DSIP
Directly enhances delta-wave (slow-wave) sleep architecture; addresses the “slept eight hours but woke up exhausted” patient. Non-sedating and non-habit-forming.
-
Epithalon
Pineal-derived peptide that regulates melatonin production and circadian rhythm; restores the natural sleep-wake cycle, particularly relevant where night sweats have fragmented sleep continuity.
Addresses both core dimensions of sleep — architecture and circadian timing — without morning grogginess or dependency.
-
DSIP
Enhances delta-wave sleep architecture, addressing restorative depth.
-
Epithalon
Pineal-derived peptide regulating melatonin and circadian rhythm.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog with selective GH secretagogue; the largest natural GH pulse occurs during deep sleep, and restoring this pattern feeds back to amplify sleep depth.
-
N-Acetyl Selank
Anxiolytic neuropeptide reducing pre-sleep anxious arousal and racing thoughts without sedation or morning grogginess.
-
Pinealonbioregulator
Pineal and CNS tissue-specific bioregulator supporting the structural integrity of circadian centers.
Addresses architecture loss, circadian drift, GH-pulse decline, and pre-sleep arousal simultaneously, producing more durable improvement than any single intervention.
-
DSIP
Enhances delta-wave sleep architecture.
-
Epithalon
Pineal-derived peptide regulating melatonin and circadian rhythm.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog amplifying the deep-sleep GH pulse.
-
N-Acetyl Selank
Anxiolytic neuropeptide reducing pre-sleep arousal.
-
Pinealonbioregulator
Pineal/CNS tissue-specific bioregulator.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator; addresses the cortisol dysregulation pattern underlying much of perimenopausal insomnia.
-
NAD+
Mitochondrial cofactor; sleep is the primary state for cellular repair and NAD+ utilization.
-
Oxytocin
Parasympathetic-activating neuropeptide; promotes the calm, connected state that facilitates sleep onset and reduces sympathetic overdrive, including the autonomic surge that precedes night sweats.
Covers sleep architecture, circadian timing, GH-axis amplification, anxiolysis, parasympathetic activation, HPA cortisol normalization, and mitochondrial restoration.
Joint Pain / Muscle Aches
Direct tissue repair via the foundational repair peptide pairing. Joint and muscle pain are reported by 85–88% of women in menopausal symptom cohorts, frequently linked to the anti-inflammatory effects lost with declining estrogen.
-
BPC-157
Pentadecapeptide derived from gastric juice; promotes angiogenesis, accelerates tendon and ligament healing, modulates the inflammatory response, and has documented effects on cartilage repair.
-
TB-500
Actin-binding peptide that promotes cell migration, vascularization, and tissue regeneration; pairs synergistically with BPC-157 by addressing cellular mobility and revascularization.
The most validated tissue-repair stack in regenerative peptide medicine — patient typically reports reduced joint pain and improved range of motion within 2–4 weeks.
-
BPC-157
Promotes angiogenesis, tendon/ligament healing, and cartilage repair.
-
TB-500
Cell migration, vascularization, and tissue regeneration.
-
KPV
Tripeptide derived from alpha-MSH; potent anti-inflammatory active suppressing NF-κB signaling and reducing pro-inflammatory cytokine production systemically — relevant given the loss of estrogen's anti-inflammatory effect.
-
Cartalaxbioregulator
Cartilage tissue-specific bioregulator targeting structural integrity of cartilage at the cellular level.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog with selective GH secretagogue; restores GH/IGF-1 signaling that drives connective tissue synthesis and overnight repair.
Spans local tissue repair, systemic inflammation control, specific cartilage bioregulation, and the GH-axis recovery substrate.
-
BPC-157
Angiogenesis, tendon/ligament healing, inflammatory modulation.
-
TB-500
Cell migration, vascularization, tissue regeneration.
-
KPV
Anti-inflammatory tripeptide suppressing NF-κB signaling systemically.
-
Cartalaxbioregulator
Cartilage tissue-specific bioregulator.
-
CJC-1295 No DAC / Ipamorelin
GH/IGF-1 signaling for connective tissue synthesis.
-
Thymosin Alpha-1
Immune-modulating peptide; rebalances the inflammatory/regulatory T-cell ratio that often underlies chronic systemic inflammation and autoimmune-spectrum joint pain, which disproportionately affects women.
-
GHK-Cu
Tripeptide-copper complex promoting collagen synthesis, extracellular matrix remodeling, and anti-inflammatory gene expression.
-
NAD+
Mitochondrial cofactor supporting the metabolic capacity required for tissue repair.
Covers local tissue repair, cartilage bioregulation, systemic anti-inflammatory pathways, immune rebalancing, GH-axis anabolic substrate, and mitochondrial energy.
Vaginal Dryness / Atrophy (Genitourinary Syndrome of Menopause)
Direct tissue and mucosal repair, addressing the vulvovaginal and urinary tissue changes that follow declining estrogen. Affects a substantial proportion of postmenopausal women and is frequently underreported relative to its impact on quality of life.
-
BPC-157
Pentadecapeptide with documented effects on mucosal tissue repair and angiogenesis; supports vulvovaginal tissue regeneration and addresses the thinning, fragile mucosa characteristic of genitourinary syndrome of menopause.
-
Oxytocin
Supports tissue blood flow and arousal-related vasocongestion, and has direct trophic effects on smooth muscle and mucosal tissue relevant to vaginal physiology.
Addresses tissue-level repair and local blood flow without systemic hormone, suitable as a first-line option or adjunct for patients who are not candidates for or prefer to avoid local estrogen therapy.
-
BPC-157
Mucosal tissue repair and angiogenesis supporting vulvovaginal regeneration.
-
Oxytocin
Tissue blood flow and trophic support for smooth muscle and mucosal tissue.
-
GHK-Cu
Tripeptide-copper complex promoting collagen synthesis and extracellular matrix remodeling, directly relevant to the structural collagen loss underlying vaginal and vulvar tissue thinning.
-
Vesilutebioregulator
Bladder and urogenital tissue-specific bioregulator supporting the structural and functional integrity of urogenital tissue at the cellular level — directly relevant given the urinary symptoms (urgency, recurrent UTI risk) that frequently accompany genitourinary syndrome of menopause.
-
NAD+
Mitochondrial cofactor supporting cellular regeneration in the rapidly turning-over epithelial tissue of the vulvovaginal mucosa.
Adds the structural collagen substrate, bladder/urogenital tissue bioregulation, and cellular energy support to the mucosal repair foundation.
-
BPC-157
Mucosal tissue repair and angiogenesis.
-
Oxytocin
Tissue blood flow and trophic support.
-
GHK-Cu
Collagen synthesis and extracellular matrix remodeling.
-
Vesilutebioregulator
Bladder and urogenital tissue-specific bioregulator.
-
TB-500
Actin-binding peptide supporting cell migration and revascularization, complementing BPC-157 in tissue that depends heavily on local blood flow.
-
NAD+
Mitochondrial cofactor for epithelial cellular regeneration.
-
KPV
Anti-inflammatory tripeptide; addresses the low-grade chronic inflammation that can accompany atrophic tissue changes and contribute to discomfort.
-
Glutathione
Master antioxidant supporting tissue resilience against oxidative stress, relevant to the accelerated tissue aging seen in estrogen-deficient mucosa.
Covers mucosal repair, tissue blood flow, collagen substrate, urogenital tissue bioregulation, revascularization, mitochondrial regeneration, anti-inflammatory action, and oxidative stress resilience.
Loss of Muscle Mass / Strength Decline
Direct anabolic stimulation via GH and IGF-1 pathways. Sarcopenia accelerates meaningfully after menopause as the protective effect of estrogen on muscle protein synthesis declines, often compounding with reduced activity levels.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog paired with a selective GH secretagogue; restores youthful nocturnal GH pulses, driving lean mass gain, recovery, and body composition improvement. The foundational anabolic peptide stack.
-
IGF-1 LR3
Long-acting IGF-1 analog; directly activates the downstream anabolic pathway responsible for muscle protein synthesis, satellite cell activation, and hypertrophy.
Pulsatile GH at the top of the cascade and direct IGF-1 substrate at the bottom — the classic anabolic peptide introduction.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog with selective GH secretagogue; drives lean mass gain and recovery.
-
IGF-1 LR3
Long-acting IGF-1 analog activating muscle protein synthesis and hypertrophy.
-
BPC-157 / TB-500
Angiogenic and tissue-repair peptide pairing; accelerates tendon, ligament, and muscle recovery from training stress, allowing higher training volume without injury accumulation.
-
MK-677 (Ibutamoren)
Orally bioavailable GH secretagogue; produces sustained 24-hour elevation of GH and IGF-1, complementing the pulsatile pattern of CJC/Ipamorelin.
May cause water retention, increased appetite, and transient insulin resistance.
Addresses the three rate-limiters of muscle building during and after the menopausal transition: anabolic signaling, sustained GH/IGF-1 elevation, and recovery capacity.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog with selective GH secretagogue.
-
IGF-1 LR3
Long-acting IGF-1 analog activating muscle protein synthesis.
-
MK-677 (Ibutamoren)
Orally bioavailable GH secretagogue with sustained 24-hour GH/IGF-1 elevation.
May cause water retention, increased appetite, and transient insulin resistance. -
BPC-157
Angiogenic and tissue-repair peptide; accelerates tendon, ligament, and muscle recovery.
-
TB-500
Actin-binding peptide promoting cell migration, vascularization, and tissue regeneration; pairs synergistically with BPC-157.
-
SLU-PP-332
ERR agonist and exercise mimetic; upregulates mitochondrial biogenesis and fatty acid oxidation, producing exercise-like adaptations that amplify training response.
-
MOTS-c
Mitochondrial-derived peptide improving metabolic flexibility and exercise capacity, addressing mitochondrial dysfunction that limits training performance and recovery.
-
5-Amino-1MQ
Selective NNMT inhibitor; increases adipocyte NAD+ availability and supports lean mass through a mechanism distinct from GH-axis actives.
Covers pulsatile and sustained GH signaling, direct IGF-1 substrate, tissue recovery, mitochondrial and exercise-mimetic enhancement, and enzymatic lean-mass preservation.
Skin Aging / Collagen Loss
Direct collagen synthesis and skin regeneration through the two most validated skin peptides. Women lose a disproportionate share of dermal collagen in the years immediately following menopause, making this a high-frequency longevity-clinic complaint.
-
GHK-Cu
Tripeptide-copper complex; the most extensively studied peptide for skin health, with documented effects on collagen synthesis, elastin production, wound healing, and dermal remodeling. Directly addresses the accelerated collagen decline that follows declining estrogen.
-
Epithalon
Pineal-derived peptide with systemic anti-aging effects; documented to improve skin appearance and elasticity through telomerase-supportive mechanisms.
Targets skin aging through two distinct mechanisms — direct extracellular matrix remodeling and systemic cellular longevity.
-
GHK-Cu
Foundational anti-aging skin peptide.
-
Epithalon
Systemic anti-aging effects via telomerase support.
-
CJC-1295 No DAC / Ipamorelin
Restores GH/IGF-1 signaling that drives dermal collagen synthesis and skin thickness, both of which decline sharply in the early postmenopausal years.
-
BPC-157
Promotes angiogenesis and improves cutaneous microcirculation, supporting the vascular substrate of skin health.
-
NAD+
Supports cellular bioenergetics in fibroblasts and keratinocytes, the cells responsible for skin regeneration.
Covers local extracellular matrix remodeling, systemic longevity, GH-axis substrate, cutaneous vascular health, and cellular bioenergetics.
-
GHK-Cu
Foundational anti-aging skin peptide.
-
AHK-Cu
Complementary copper peptide with different documented skin effects, broadening coverage of copper peptide pathways.
-
Epithalon
Systemic anti-aging peptide.
-
CJC-1295 No DAC / Ipamorelin
GH/IGF-1 signaling for dermal collagen synthesis.
-
BPC-157
Angiogenesis and cutaneous microcirculation.
-
TB-500
Supports dermal stem cell activity and cutaneous wound healing.
-
NAD+
Mitochondrial cofactor for fibroblast and keratinocyte function.
-
Glutathione
Master antioxidant addressing the oxidative damage that drives photoaging, compounded by the loss of estrogen's antioxidant-supportive effects on skin.
-
KPV
Suppresses cutaneous inflammation and NF-κB signaling, addressing the inflammatory component of intrinsic and extrinsic skin aging.
Covers extracellular matrix and collagen synthesis, systemic longevity, GH-axis dermal substrate, cutaneous vascular and stem cell support, mitochondrial energy, oxidative stress control, and anti-inflammatory pathways.
Hair Thinning / Loss
Direct follicle stimulation via copper peptides and vascular support. Female pattern hair thinning frequently accelerates around the menopausal transition as the relative balance of estrogen and androgen shifts.
-
GHK-Cu
Tripeptide-copper complex; the most extensively studied peptide for hair growth, with documented effects on follicle size, dermal papilla cell proliferation, and transition from telogen to anagen phase.
-
AHK-Cu
Tripeptide-copper complex with stronger documented hair-growth specificity than GHK-Cu; research specifically focused on hair density and anagen phase induction.
Direct hair-growth actives that work through follicular biology rather than hormonal manipulation, appropriate regardless of the androgen-relative-excess pattern common in female pattern thinning.
-
GHK-Cu
Foundational hair-growth active supporting follicle size and anagen-phase induction.
-
AHK-Cu
Stronger documented hair-growth specificity than GHK-Cu.
-
CJC-1295 No DAC / Ipamorelin
GH and IGF-1 directly drive the anagen phase of hair growth; restoring youthful GH signaling supports follicular cycling.
-
BPC-157
Promotes angiogenesis and vascular health, improving scalp microcirculation that feeds follicles.
-
TB-500
Supports follicular stem cell activity and scalp vascularity.
Covers direct follicle stimulation, systemic anabolic signaling, and scalp vascular health — for patients who haven't fully responded to topical actives.
-
GHK-Cu
Foundational hair-growth active.
-
AHK-Cu
Stronger documented hair-growth specificity.
-
CJC-1295 No DAC / Ipamorelin
Supports follicular cycling via GH/IGF-1 signaling.
-
IGF-1 LR3
IGF-1 is the most important growth factor in the dermal papilla; direct substrate amplifies anagen-phase signaling.
-
BPC-157
Scalp angiogenesis and vascular health.
-
TB-500
Follicular stem cell activity and scalp vascularity.
-
Thymulinbioregulator
Zinc-thymulin bioregulator with documented anti-inflammatory effects on hair follicles, relevant given the inflammatory and autoimmune-adjacent component sometimes seen in female pattern hair loss.
-
NAD+
Follicular stem cells are highly metabolically active; NAD+ depletion contributes to age-related follicular miniaturization.
-
KPV
Suppresses scalp inflammation and NF-κB signaling, addressing the inflammatory component of follicular miniaturization.
Covers direct follicular stimulation, GH-axis and IGF-1 follicular signaling, scalp vascular health, follicular anti-inflammatory pathways, and mitochondrial substrate.
PMS / PMDD (Perimenopausal & Reproductive-Age)
Direct anxiolysis and rapid mood support targeting the cyclical, luteal-phase symptom pattern distinct from menopausal mood change. PMDD affects a meaningful minority of reproductive-age women with severity that can be functionally disabling in the luteal phase.
-
N-Acetyl Selank
Anxiolytic neuropeptide that modulates GABA and serotonin systems; reduces the irritability, anxiety, and emotional lability characteristic of the luteal-phase symptom cluster, without sedation.
-
PE-22-28
Synthetic spadin analog and TREK-1 potassium channel blocker; produces rapid antidepressant-like effects, useful given the time-limited and predictable nature of luteal-phase symptoms where rapid onset matters more than with continuous depression.
Both actives have fast enough onset to be used proactively in the days preceding expected symptom onset, rather than requiring weeks of continuous dosing like SSRIs.
-
N-Acetyl Selank
Anxiolytic neuropeptide reducing luteal-phase irritability and emotional lability.
-
PE-22-28
Rapid antidepressant-like effects suited to the time-limited luteal-phase pattern.
-
Oxytocin
Supports emotional regulation and reduces stress reactivity; oxytocin signaling fluctuates across the menstrual cycle and may buffer the mood sensitivity seen in PMDD.
-
NAD+
Mitochondrial cofactor supporting cellular energy; some research implicates mitochondrial and inflammatory sensitivity to hormonal fluctuation in PMDD symptom severity.
Adds oxytocinergic mood buffering and cellular energy substrate to the core anxiolytic/rapid-antidepressant pairing.
-
N-Acetyl Selank
Anxiolytic neuropeptide modulating GABA and serotonin systems.
-
PE-22-28
Rapid antidepressant-like effects.
-
Oxytocin
Emotional regulation and stress reactivity buffering.
-
NAD+
Cellular energy substrate.
-
N-Acetyl Semax
Neuropeptide upregulating BDNF and dopamine signaling, addressing the motivational flatness and brain fog that frequently accompany the luteal-phase symptom cluster.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator; supports HPA axis function, which interacts with the hormonal sensitivity underlying PMDD symptom severity.
-
KPV
Anti-inflammatory tripeptide; addresses the low-grade inflammatory component increasingly implicated in PMDD symptom severity.
Covers anxiolytic and rapid-antidepressant pathways, oxytocinergic mood buffering, cellular energy, dopaminergic/cognitive support, HPA axis function, and anti-inflammatory action.
Pre-Diabetes / Insulin Resistance
Direct glycemic control via the incretin pathway. Insulin resistance risk rises meaningfully after menopause as the protective metabolic effect of estrogen on glucose handling declines.
The two GLP-class actives below are either/or options, not a combined stack. Choose one based on patient profile; they are not used together.
-
Semaglutide (GLP-1S)Option A
GLP-1 receptor agonist; improves insulin sensitivity, suppresses glucagon, slows gastric emptying, and produces meaningful weight loss. Preferred for cost-sensitive or moderate-severity patients.
-
Tirzepatide (GLP-2T)Option B
Dual GLP-1/GIP receptor agonist; stronger glycemic control and weight loss than semaglutide, with superior HbA1c reduction. Preferred for higher BMI or established metabolic syndrome.
Choose one GLP-class active as the incretin backbone (as in the beginner tier); the remaining actives below stack on top of it.
-
MOTS-c
Mitochondrial-derived peptide directly improving insulin sensitivity at the muscle and adipose cellular level, independent of weight loss.
-
AICAR
AMPK activator improving cellular glucose uptake and fatty acid oxidation through a pathway entirely separate from incretins; mimics the metabolic effects of exercise.
-
5-Amino-1MQ
Selective NNMT inhibitor increasing adipocyte NAD+ availability and supporting metabolic flexibility through a mechanism distinct from incretins or AMPK activation.
-
CJC-1295 No DAC / Ipamorelin
Restores GH signaling supporting lean mass, the largest glucose-disposal tissue, preventing the muscle loss that worsens long-term insulin resistance during the menopausal transition.
Addresses insulin resistance at the cellular and non-incretin glucose-handling levels — for patients where GLP-1 weight loss alone hasn't normalized HbA1c.
Retatrutide is listed as the single incretin backbone at this tier. It is not stacked with Semaglutide or Tirzepatide — only one GLP-class active is used at a time.
-
Retatrutide (GLP-3R)incretin backbone
Triple agonist (GLP-1, GIP, glucagon); the glucagon component supports hepatic fat oxidation, addressing fatty liver, a major driver of insulin resistance.
-
Cagrilintide
Long-acting amylin analog complementing incretin action through a separate satiety pathway, improving post-prandial glucose control.
-
MOTS-c
Mitochondrial-derived peptide directly improving cellular insulin sensitivity.
-
AICAR
AMPK activator mimicking exercise metabolic effects on insulin sensitivity.
-
5-Amino-1MQ
Selective NNMT inhibitor supporting metabolic flexibility.
-
SLU-PP-332
ERR agonist and exercise mimetic upregulating mitochondrial biogenesis and fatty acid oxidation.
-
CJC-1295 No DAC / Ipamorelin
Restores GH signaling supporting lean mass, the largest glucose-disposal tissue.
-
NAD+
Mitochondrial cofactor; substrate for the cellular processes driving insulin signaling and glucose metabolism.
Covers incretin and amylin glycemic control, mitochondrial insulin sensitivity, non-incretin glucose pathways, exercise-mimetic adaptation, and lean-mass preservation.
High Cholesterol / Cardiometabolic Risk (Post-Menopausal)
Direct cardiometabolic and mitochondrial support, addressing the lipid and cardiovascular risk shift that follows declining estrogen, which loses much of its protective effect on the vascular endothelium and lipid profile after menopause.
-
NAD+
Supports endothelial function, mitochondrial bioenergetics in cardiac tissue, and sirtuin-mediated longevity pathways, all of which are affected by the loss of estrogen's vasculoprotective effects.
-
MOTS-c
Mitochondrial-derived peptide improving metabolic flexibility and insulin sensitivity, addressing mitochondrial dysfunction that underlies cardiometabolic disease at the cellular level.
Targets endothelial and mitochondrial health rather than chasing individual lipid numbers — the foundation for any cardiometabolic optimization protocol in the postmenopausal patient.
-
NAD+
Endothelial function and mitochondrial cardiac bioenergetics.
-
MOTS-c
Metabolic flexibility and insulin sensitivity.
-
Semaglutide (GLP-1S)
GLP-1 receptor agonist with documented cardiovascular outcome benefit independent of weight loss; reduces major adverse cardiovascular events in clinical trials.
-
Cardiogenbioregulator
Cardiac tissue-specific bioregulator targeting the structural and functional integrity of cardiac tissue at the cellular level.
-
Vesugenbioregulator
Vascular tissue-specific bioregulator addressing the vascular endothelium and smooth muscle that lose estrogen's protective signaling after menopause.
Spans cellular bioenergetics, incretin-mediated metabolic control, and direct cardiac/vascular tissue substrate.
-
NAD+
Endothelial function and mitochondrial cardiac bioenergetics.
-
MOTS-c
Metabolic flexibility and insulin sensitivity.
-
Semaglutide (GLP-1S)
Documented cardiovascular outcome benefit.
-
Cardiogenbioregulator
Cardiac tissue-specific bioregulator.
-
Vesugenbioregulator
Vascular tissue-specific bioregulator.
-
SLU-PP-332
ERR agonist and exercise mimetic producing exercise-like metabolic adaptations in cardiac and skeletal muscle.
-
KPV
Suppresses NF-κB signaling, addressing the inflammatory substrate of atherosclerotic cardiovascular disease, which accelerates after the loss of estrogen's anti-inflammatory effect.
-
Methylene Blue
Supports endothelial NO signaling and mitochondrial bioenergetics in cardiac tissue.
Contraindicated with SSRIs/SNRIs.
Covers mitochondrial cardiometabolic substrate, incretin-mediated metabolic control, cardiac/vascular tissue bioregulation, exercise-mimetic adaptation, and systemic anti-inflammatory pathways.
Bone Density Loss / Osteoporosis Risk
Direct bone-forming substrate, addressing the rapid acceleration of bone loss that follows the decline of estrogen, the primary regulator of osteoclast activity in women. The years immediately following menopause carry the steepest rate of bone density loss in the female lifespan.
-
Teriparatide
Recombinant PTH (1-34) analog; the only true anabolic bone-forming agent in clinical use, directly stimulating osteoblast activity and increasing bone formation. FDA-approved for osteoporosis with documented fracture risk reduction, and one of the few interventions that builds new bone rather than only slowing loss.
-
CJC-1295 No DAC / Ipamorelin
GH and IGF-1 directly support bone mineral density through osteoblast stimulation and are major contributors to peak bone mass and bone maintenance, complementing teriparatide's anabolic effect.
Pairs the most powerful anabolic bone agent available with the systemic anabolic environment for sustained bone density improvement. Patient sees measurable DEXA improvement within 12–24 months.
-
Teriparatide
Anabolic bone-forming agent.
-
CJC-1295 No DAC / Ipamorelin
GH-axis bone support.
-
GHK-Cu
Supports collagen synthesis, the protein matrix of bone, addressing structural protein substrate of bone strength beyond mineralization.
-
NAD+
Supports osteoblast function and the cellular bioenergetics required for bone remodeling.
Spans direct anabolic bone formation, GH-axis bone support, collagen matrix, and mitochondrial bone cell function.
-
Teriparatide
Anabolic bone-forming PTH analog.
-
CJC-1295 No DAC / Ipamorelin
GH-axis bone support.
-
IGF-1 LR3
Direct anabolic substrate driving osteoblast proliferation and bone matrix synthesis.
-
GHK-Cu
Collagen and extracellular matrix substrate.
-
NAD+
Mitochondrial cofactor for osteoblast function.
-
KPV
Addresses the chronic low-grade inflammation that accelerates bone loss and impairs osteoblast function, compounded by the loss of estrogen's anti-inflammatory effect.
-
BPC-157
Supports angiogenesis and the vascular substrate that delivers nutrients to bone.
-
SLU-PP-332
Produces exercise-like mechanical loading adaptations supporting bone density, valuable for sedentary or mobility-limited patients.
-
MOTS-c
Supports metabolic flexibility and insulin sensitivity that determine bone health.
Covers PTH anabolic bone formation, GH-axis and IGF-1, collagen matrix, mitochondrial bone cell function, anti-inflammatory action, bone vascular substrate, and exercise-mimetic mechanical adaptation.
Recovery / Performance Optimization
Direct tissue recovery via the same foundational repair pairing, applied to systemic training and exertion recovery. Ideal for the active patient seeking faster recovery between sessions, particularly relevant as recovery capacity declines through the menopausal transition.
-
BPC-157
Promotes angiogenesis, tendon/ligament healing, and inflammatory modulation; addresses soft tissue stress accumulated during training.
-
TB-500
Actin-binding peptide promoting cell migration, vascularization, and tissue regeneration; accelerates recovery from training-induced microtrauma.
The foundational recovery stack for the athletic patient — reduced post-training soreness and faster return-to-training within 2 weeks.
-
BPC-157
Angiogenesis, tendon/ligament healing.
-
TB-500
Cell migration, vascularization, tissue regeneration.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog restoring the nocturnal GH pulse that drives most overnight tissue repair and metabolic recovery from training.
-
MOTS-c
Mitochondrial-derived peptide improving metabolic flexibility and exercise capacity, addressing the mitochondrial substrate that determines both training capacity and recovery rate.
-
DSIP
Enhances delta-wave sleep architecture; recovery is sleep-dependent, and deepening sleep amplifies the output of every other active in the stack.
Covers local tissue repair, systemic anabolic signaling, cellular bioenergetics, and the sleep substrate during which recovery actually occurs.
-
BPC-157
Angiogenesis and tendon/ligament healing.
-
TB-500
Cell migration, vascularization, tissue regeneration.
-
CJC-1295 No DAC / Ipamorelin
Nocturnal GH pulse driving overnight tissue repair.
-
IGF-1 LR3
Direct anabolic substrate accelerating muscle protein synthesis and recovery.
-
MOTS-c
Mitochondrial-derived peptide for metabolic flexibility and exercise capacity.
-
SLU-PP-332
ERR agonist and exercise mimetic; amplifies training adaptations and recovery between sessions.
-
DSIP
Enhances delta-wave sleep architecture for overnight recovery.
-
KPV
Anti-inflammatory tripeptide controlling systemic inflammatory load from training without blunting the adaptive response.
Covers local tissue repair, GH-axis and IGF-1 anabolic signaling, mitochondrial and exercise-mimetic adaptation, sleep architecture, and controlled anti-inflammatory tone.
Chronic Joint/Tendon Pain — Peptide Repair Seekers
Foundational repair peptide pairing delivered directly to the patient's identified injury or chronic pain site, for the educated peptide-seeker who already knows what they want.
-
BPC-157
Promotes angiogenesis, accelerates tendon and ligament healing, modulates the inflammatory response, and has documented effects on cartilage repair. The active most peptide-seekers ask for by name.
-
TB-500
Actin-binding peptide promoting cell migration, vascularization, and tissue regeneration; the standard companion to BPC-157 in peptide repair protocols.
Delivers exactly what the educated peptide-seeker patient is asking for — matches patient expectations and avoids over-prescribing friction.
-
BPC-157
Angiogenesis, tendon/ligament healing, inflammatory modulation.
-
TB-500
Cell migration, vascularization, tissue regeneration.
-
Cartalaxbioregulator
Cartilage tissue-specific bioregulator, particularly valuable for joint surface degeneration or osteoarthritic involvement, which accelerates after menopause.
-
KPV
Anti-inflammatory tripeptide addressing the chronic inflammatory substrate that perpetuates pain even after structural healing.
-
CJC-1295 No DAC / Ipamorelin
Provides the anabolic environment required for sustained tissue repair, particularly relevant as endogenous GH/IGF-1 signaling declines through midlife.
Covers tendon/ligament repair, cartilage substrate, systemic inflammation, and the anabolic environment — for patients whose chronic pain has plateaued on the basic repair stack.
-
BPC-157
Angiogenesis and tendon/ligament healing.
-
TB-500
Cell migration, vascularization, tissue regeneration.
-
Cartalaxbioregulator
Cartilage tissue-specific bioregulator.
-
GHK-Cu
Promotes collagen synthesis and extracellular matrix remodeling, addressing the collagen substrate that determines connective tissue strength.
-
KPV
Anti-inflammatory tripeptide suppressing NF-κB signaling.
-
CJC-1295 No DAC / Ipamorelin
Anabolic environment for sustained tissue repair.
-
IGF-1 LR3
Direct anabolic substrate driving cellular proliferation, particularly valuable for tendons with notoriously poor vascular supply.
-
Thymosin Alpha-1
Immune-modulating peptide rebalancing the inflammatory/regulatory ratio where immune dysregulation perpetuates the inflammatory state.
-
NAD+
Mitochondrial cofactor providing cellular energy substrate for active tissue repair.
Covers tendon/ligament repair, cartilage bioregulation, collagen synthesis, anti-inflammatory pathways, GH-axis/IGF-1 anabolic signaling, immune rebalancing, and mitochondrial energy.
Post-GLP-1 Plateau / Muscle Preservation
Direct muscle preservation and targeted lipolysis addressing the two most common failure points of GLP-1 monotherapy. Particularly important for women, who lose proportionally more lean mass relative to total weight loss than men on the same incretin regimens.
-
CJC-1295 No DAC / Ipamorelin
Pulsatile GHRH analog with selective GH secretagogue; preserves and builds lean muscle mass during caloric restriction, preventing the sarcopenic pattern that develops with GLP-1 monotherapy and compounds with the menopausal decline in muscle mass.
-
AOD9604
Modified GH fragment selectively stimulating lipolysis and inhibiting lipogenesis without affecting blood glucose, IGF-1, or muscle protein synthesis.
Addresses the two failure modes of basic GLP-1 weight loss simultaneously — muscle wasting and the lipolytic ceiling — both of which carry outsized impact in the perimenopausal and postmenopausal patient.
-
CJC-1295 No DAC / Ipamorelin
Preserves and builds lean muscle mass.
-
AOD9604
Selective lipolysis without affecting blood glucose or IGF-1.
-
MOTS-c
Mitochondrial-derived peptide reversing the “starvation mode” mitochondrial adaptation that stalls weight loss after initial progress.
-
SLU-PP-332
ERR agonist and exercise mimetic producing exercise-like metabolic adaptations that break through the metabolic plateau.
Addresses muscle preservation, targeted lipolysis, mitochondrial flexibility, and exercise-mimetic adaptation together.
-
CJC-1295 No DAC / Ipamorelin
Muscle preservation foundation.
-
IGF-1 LR3
Direct anabolic substrate accelerating muscle protein synthesis during caloric restriction.
-
AOD9604
Selective lipolysis.
-
MOTS-c
Metabolic flexibility restoration.
-
5-Amino-1MQ
Selective NNMT inhibitor supporting lean mass through a mechanism distinct from GH or GLP-1 pathways.
-
SLU-PP-332
Mitochondrial biogenesis and fatty acid oxidation.
-
DSIP
Largest GH pulse occurs during deep sleep, amplifying the muscle-preserving and fat-burning effects of the GH-axis stack.
-
MK-677 (Ibutamoren)
Sustained 24-hour GH/IGF-1 elevation complementing pulsatile signaling.
May cause water retention, increased appetite, and transient insulin resistance.
Covers pulsatile and sustained GH signaling, direct IGF-1 substrate, selective lipolysis, mitochondrial flexibility, exercise-mimetic adaptation, and sleep-driven GH amplification.
General Optimization / “Feel Younger” (Asymptomatic)
Foundational longevity substrate and mitochondrial support for the proactive optimizer with no specific complaint. Simple, broad, and high patient-perceivable response.
-
NAD+
Central mitochondrial cofactor for the electron transport chain and sirtuin substrate; the foundational longevity active. Typically produces energy improvement, cognitive clarity, and recovery enhancement.
-
Epithalon
Pineal-derived peptide with the strongest longevity research evidence in the catalog; restores circadian rhythm, supports telomerase activity, and is most often associated with biological age reversal in the longevity literature.
Addresses cellular bioenergetics and the pineal/circadian longevity axis — broad subjective improvement without targeting any specific complaint.
-
NAD+
Foundational mitochondrial cofactor.
-
Epithalon
Pineal-derived longevity peptide.
-
CJC-1295 No DAC / Ipamorelin
Restores youthful nocturnal GH pulses, addressing the GH-axis decline that drives the majority of subjective aging symptoms.
-
MOTS-c
Mitochondrial-derived peptide upregulating mitochondrial biogenesis.
-
FOX04-DRI
Senolytic peptide; selectively induces apoptosis in senescent cells while sparing healthy cells, addressing the accumulation that drives age-related inflammation and tissue dysfunction.
Targets five distinct hallmarks of aging simultaneously — cellular energy, mitochondrial biogenesis, pineal/circadian longevity, GH-axis restoration, and senescent cell clearance.
-
NAD+
Foundational mitochondrial cofactor.
-
Epithalon
Pineal-derived longevity peptide with telomerase support.
-
CJC-1295 No DAC / Ipamorelin
Restores youthful GH pulses.
-
MOTS-c
Upregulates mitochondrial biogenesis.
-
FOX04-DRI
Senolytic peptide clearing senescent cells.
-
Humanin
Mitochondrial-derived peptide with documented neuroprotective, cardioprotective, and longevity effects, complementing MOTS-c through a parallel signaling pathway.
-
Pinealonbioregulator
Pineal/CNS tissue-specific bioregulator supporting neurological longevity and cognitive resilience.
-
SLU-PP-332
ERR agonist and exercise mimetic complementing, not replacing, actual exercise.
-
SS-31
Mitochondria-targeted peptide stabilizing the inner mitochondrial membrane and reducing reactive oxygen species, the most advanced anti-oxidative mitochondrial active available.
Covers mitochondrial substrate and biogenesis, GH-axis restoration, senolytic clearance, pineal/circadian longevity, exercise-mimetic adaptation, and mitochondrial membrane stabilization.
Chronic Stress / “Adrenal Fatigue” / HPA Axis Dysregulation
Direct anxiolysis and adrenal bioregulator support, working centrally and at the adrenal level without requiring labs or complex protocols. The interplay between cortisol and declining ovarian hormones makes HPA dysregulation a particularly common presentation in perimenopausal women.
-
N-Acetyl Selank
Anxiolytic neuropeptide that modulates GABA and serotonin systems; reduces stress reactivity, anxious arousal, and the sympathetic overdrive that underlies chronic HPA activation.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator supporting the structural and functional integrity of the adrenal cortex at the cellular level, addressing depleted adrenal substrate.
Targets the two ends of the HPA dysregulation picture — central anxiolytic control and adrenal tissue substrate.
-
N-Acetyl Selank
Anxiolytic neuropeptide for stress reactivity.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator.
-
N-Acetyl Semax
Upregulates BDNF and dopamine signaling, restoring motivation and drive deficits characteristic of late-stage chronic stress and burnout.
-
DSIP
Chronic stress fragments sleep and blunts deep sleep; restoring slow-wave sleep is essential for HPA recovery and cortisol rhythm normalization.
-
NAD+
Chronic stress depletes cellular energy substrate; NAD+ restoration addresses the bioenergetic exhaustion underlying “adrenal fatigue” presentations.
Covers anxiolytic, dopaminergic resilience, adrenal tissue substrate, sleep restoration, and cellular energy together.
-
N-Acetyl Selank
Anxiolytic neuropeptide for stress reactivity.
-
N-Acetyl Semax
Dopaminergic resilience and motivational restoration.
-
Cortagenbioregulator
Adrenal cortex tissue-specific bioregulator.
-
Pinealonbioregulator
Pineal/CNS tissue-specific bioregulator supporting circadian rhythm regulation that underlies cortisol normalization.
-
DSIP
Slow-wave sleep architecture restoration.
-
Epithalon
Supports circadian rhythm and cortisol patterning at the systemic level.
-
NAD+
Cellular energy restoration.
-
PE-22-28
Addresses the depressive/anhedonic component of late-stage chronic stress with rapid antidepressant effects.
-
Oxytocin
Counterbalances sympathetic overdrive and supports HPA recovery through the social-bonding stress-buffering pathway.
Covers anxiolytic, dopaminergic resilience, adrenal tissue substrate, pineal/circadian regulation, sleep architecture, cellular energy, rapid antidepressant pathway, and parasympathetic activation.
Gut Issues (Bloating, IBS-Type Symptoms)
Direct GI tissue repair via the foundational gut peptides, covering the two dominant mechanisms in functional gut complaints: mucosal repair and intestinal inflammation. IBS-spectrum symptoms are diagnosed roughly twice as often in women as in men, with symptom severity frequently fluctuating across the menstrual cycle and menopausal transition.
-
BPC-157
Pentadecapeptide originally derived from gastric juice; the most extensively studied gut-healing peptide, with documented effects on gastric and intestinal mucosal repair, tight junction integrity, and inflammatory modulation.
-
KPV
Potent anti-inflammatory active suppressing NF-κB signaling specifically in the gut mucosa, addressing the inflammatory component of IBS, IBD, and functional GI disorders.
Patient typically reports reduced bloating, improved bowel regularity, and decreased post-meal discomfort within 2–4 weeks.
-
BPC-157
Foundational gut mucosal repair.
-
KPV
Anti-inflammatory gut mucosal protection.
-
Livagenbioregulator
Liver tissue-specific bioregulator supporting hepatic detoxification and bile production, addressing the upper-GI component of bloating, including the estrogen-metabolism load the liver carries.
-
Pancregenbioregulator
Pancreatic tissue-specific bioregulator supporting digestive enzyme production and exocrine function, addressing maldigestion-related bloating.
-
LL-37
Antimicrobial peptide addressing small intestinal bacterial overgrowth (SIBO) and dysbiosis-driven symptoms without disrupting the broader microbiome.
Spans mucosal repair, inflammation, hepatic and pancreatic digestive substrate, and microbiome-relevant antimicrobial action.
-
BPC-157
Foundational gut mucosal repair.
-
KPV
Anti-inflammatory gut mucosal protection.
-
Livagenbioregulator
Liver tissue-specific bioregulator for hepatic detoxification, including estrogen-metabolism support.
-
Pancregenbioregulator
Pancreatic tissue-specific bioregulator for digestive enzymes.
-
LL-37
Antimicrobial peptide for dysbiosis and SIBO.
-
Thymosin Alpha-1
Immune-modulating peptide rebalancing gut-associated lymphoid tissue (GALT) immune response.
-
Oxytocin
Addresses the gut-brain axis by shifting autonomic tone away from sympathetic overdrive, implicated in stress-driven IBS, which is diagnosed at roughly twice the rate in women.
-
NAD+
The intestinal epithelium is among the most metabolically demanding tissues; NAD+ supports cellular regeneration of the gut lining.
Covers mucosal repair, anti-inflammatory action, hepatic and digestive enzyme substrate, antimicrobial defense, immune rebalancing, gut-brain axis restoration, and mitochondrial substrate.
Thyroid Dysfunction Symptoms
Foundational metabolic and mitochondrial support addressing the downstream symptoms of thyroid dysfunction — fatigue, cold intolerance, weight gain, cognitive slowing — since the catalog does not contain direct thyroid hormones. Autoimmune thyroid disease occurs five to eight times more frequently in women than men, making this a high-relevance complaint in a female-focused practice.
-
NAD+
Addresses cellular energy depletion underlying the fatigue and metabolic slowing of hypothyroid presentations, providing substrate for the energy production thyroid hormone normally drives.
-
MOTS-c
Improves metabolic flexibility and insulin sensitivity; particularly relevant since thyroid hormone primarily acts on mitochondria.
Provides meaningful symptom relief while underlying thyroid pathology is evaluated and addressed separately by an endocrinologist or functional medicine practitioner.
-
NAD+
Foundational mitochondrial cofactor.
-
MOTS-c
Metabolic flexibility support.
-
CJC-1295 No DAC / Ipamorelin
GH and thyroid hormone work in concert; restoring GH signaling supports metabolic effects often blunted in subclinical thyroid dysfunction.
-
Thymosin Alpha-1
Rebalances autoimmune T-cell activity, directly relevant given that Hashimoto's thyroiditis is dramatically more prevalent in women and accounts for the majority of hypothyroid presentations seen in clinic.
Addresses mitochondrial substrate, GH-axis support, and autoimmune modulation together, with particular emphasis on the autoimmune component given female-skewed prevalence.
-
NAD+
Foundational mitochondrial cofactor.
-
MOTS-c
Metabolic flexibility support.
-
SS-31
Stabilizes the inner mitochondrial membrane, addressing mitochondrial dysfunction that may underlie persistent symptoms even with thyroid hormone normalization.
-
CJC-1295 No DAC / Ipamorelin
GH-axis support.
-
Thymosin Alpha-1
Autoimmune rebalancing, relevant to the high prevalence of Hashimoto's in women.
-
KPV
Addresses the inflammatory substrate of autoimmune thyroiditis.
-
SLU-PP-332
Exercise-like metabolic adaptations improving the metabolic profile compromised by thyroid dysfunction.
-
Cortagenbioregulator
Addresses HPA axis dysregulation that often coexists with and worsens thyroid dysfunction, particularly through the perimenopausal transition.
A comprehensive supportive protocol covering mitochondrial substrate, biogenesis, and membrane stabilization, GH-axis support, autoimmune rebalancing, anti-inflammatory action, exercise-mimetic metabolic adaptation, and HPA axis support — intended as an adjunct to thyroid hormone management, not a replacement.
Biomarker Panel / Biological Age Testing Requests
Foundational longevity actives with measurable biomarker impact, for the data-driven asymptomatic patient tracking NAD+ levels, biological age markers, and metabolic panels.
-
NAD+
The single most measurable longevity active, with documented increases in cellular NAD+ levels, sirtuin activity, and improvements in metabolic biomarkers.
-
Epithalon
Documented to support telomerase activity and produce measurable improvements on biological age assessments (epigenetic clock markers).
Produces measurable changes on the biomarker panels this patient population tracks, providing the feedback loop this patient archetype responds to.
-
NAD+
Foundational longevity cofactor.
-
Epithalon
Pineal-derived longevity peptide.
-
CJC-1295 No DAC / Ipamorelin
Produces measurable IGF-1 increases and improvements in body composition biomarkers (DEXA, InBody).
-
MOTS-c
Produces measurable improvements in insulin sensitivity, HOMA-IR, and metabolic flexibility markers.
-
FOX04-DRI
Selectively clears senescent cells, reducing markers of cellular aging and chronic inflammation (SASP markers).
Moves the most-tracked longevity biomarkers — IGF-1, HOMA-IR and metabolic markers, senescence markers, and epigenetic age.
-
NAD+
Foundational mitochondrial cofactor.
-
Epithalon
Pineal-derived longevity peptide with telomerase support.
-
CJC-1295 No DAC / Ipamorelin
IGF-1 and body composition biomarkers.
-
MOTS-c
Metabolic biomarkers.
-
Humanin
Longevity and cardioprotective biomarker effects.
-
FOX04-DRI
Senescence marker reduction.
-
SS-31
Addresses oxidative stress markers tracked on advanced panels.
-
Pinealonbioregulator
Supports cognitive biomarkers and circadian regulation.
-
SLU-PP-332
Measurable improvements in mitochondrial biogenesis markers and metabolic adaptation.
Designed to move every category of longevity biomarker tracked by sophisticated longevity panels — mitochondrial substrate, biogenesis, and membrane stabilization, GH-axis, senolytic clearance, pineal/circadian longevity, and exercise-mimetic adaptation.
Frequent Illness / Weak Immune Resilience
Direct immune modulation via the foundational immune peptides, working systemically to rebalance immune function rather than acutely suppress or stimulate.
-
Thymosin Alpha-1
Immune-modulating peptide derived from the thymus; documented to enhance T-cell maturation, NK cell activity, and adaptive immune response. The foundational immune peptide, used in oncology and immunodeficiency contexts.
-
TB-500
Actin-binding peptide supporting immune cell migration, anti-inflammatory function, and tissue repair, complementing the adaptive immune support of Thymosin Alpha-1.
Patient typically reports reduced infection frequency, faster recovery from illness, and improved overall resilience within 4–8 weeks.
-
Thymosin Alpha-1
Foundational immune-modulating peptide.
-
TB-500
Immune-regulatory and tissue-repair effects.
-
LL-37
Direct antimicrobial activity against bacteria, viruses, and fungi, addressing frontline pathogen defense.
-
Thymogenbioregulator
Thymic tissue-specific bioregulator supporting the structural and functional integrity of the thymus, the master organ of adaptive immunity that involutes with age.
-
KPV
Anti-inflammatory active preventing the inflammatory dysregulation that often coexists with immune deficiency and worsens infection recovery.
Covers adaptive immunity, innate immune cell function, direct antimicrobial defense, thymic tissue substrate, and inflammatory regulation.
-
Thymosin Alpha-1
Foundational adaptive immune peptide.
-
TB-500
Innate immune and tissue-repair peptide.
-
LL-37
Antimicrobial cathelicidin.
-
Thymogenbioregulator
Thymic tissue-specific bioregulator.
-
Thymulinbioregulator
Zinc-thymulin peptide complementing Thymogen with documented effects on T-cell maturation and immune regulation.
-
KPV
Anti-inflammatory tripeptide.
-
BPC-157
Supports mucosal barrier integrity (gut, respiratory), the primary site of pathogen entry, addressing the gut-immune axis.
-
NAD+
Immune cells are highly metabolically demanding; NAD+ supports the bioenergetic capacity required for immune function.
-
Cortagenbioregulator
Addresses chronic stress and cortisol dysregulation that suppresses immune function in many recurrent-infection patients.
Covers adaptive immunity, innate immune cells, direct antimicrobial defense, inflammatory regulation, mucosal barrier integrity, mitochondrial energy substrate, and HPA axis support.
Slow Wound Healing / Post-Surgical Recovery
Direct tissue repair foundation through the two most validated repair peptides, applied systemically to support surgical recovery, wound closure, or chronic non-healing wounds.
-
BPC-157
Promotes angiogenesis, accelerates tissue healing across virtually every tissue type tested, and modulates the inflammatory phase of wound healing.
-
TB-500
Promotes cell migration, vascularization, and tissue regeneration; addresses the cellular mobility and revascularization components essential to wound closure and remodeling.
Documented acceleration of healing across surgical, traumatic, and chronic wound contexts; patient typically reports faster healing and reduced post-surgical pain within 2 weeks.
-
BPC-157
Foundational tissue repair peptide.
-
TB-500
Cell migration and vascularization.
-
GHK-Cu
Promotes collagen synthesis, extracellular matrix remodeling, and antioxidant gene expression supporting wound healing.
-
CJC-1295 No DAC / Ipamorelin
Restores GH/IGF-1 signaling that drives wound healing, which slows measurably after the menopausal decline in estrogen and GH-axis output.
-
KPV
Suppresses NF-κB signaling and controls inflammatory tone to prevent chronic inflammation that stalls healing.
Covers tissue repair, collagen and extracellular matrix substrate, GH-axis healing environment, and controlled inflammation — particularly relevant for the postmenopausal surgical patient.
-
BPC-157
Foundational tissue repair.
-
TB-500
Cell migration and vascularization.
-
GHK-Cu
Collagen synthesis and extracellular matrix remodeling.
-
CJC-1295 No DAC / Ipamorelin
GH/IGF-1 signaling for wound healing.
-
IGF-1 LR3
Direct anabolic substrate driving cellular proliferation in the proliferative phase of wound healing.
-
KPV
Anti-inflammatory tripeptide.
-
LL-37
Addresses wound infection risk and biofilm involvement in chronic non-healing wounds.
-
Thymosin Alpha-1
Supports the immune response required for proper wound healing without inflammatory excess.
-
NAD+
Wound healing is highly energetically demanding; NAD+ supports the cellular ATP production required.
Covers tissue repair, collagen synthesis, GH-axis and IGF-1 anabolic signaling, anti-inflammatory action, antimicrobial defense, immune regulation, and mitochondrial substrate.
Early Memory Concerns / Dementia Family History
Direct cognitive enhancement and neurotrophic support, through neuropeptides that enhance current cognitive function while protecting against decline. Women carry a disproportionate lifetime risk of Alzheimer's disease, a gap increasingly linked to the cognitive effects of estrogen decline during and after menopause.
-
N-Acetyl Semax
Upregulates BDNF and modulates dopamine signaling; supports memory, attention, and the BDNF pathway implicated in age-related cognitive decline and dementia prevention.
-
DIHEXA
The most potent neurotrophic compound currently known; promotes synaptogenesis and dendritic spine formation, protecting against the synaptic loss characteristic of early Alzheimer's pathology.
Directly supports the neurotrophic and synaptic substrates that decline in early dementia; foundation for any dementia-prevention protocol, particularly relevant given the female-skewed lifetime risk.
-
N-Acetyl Semax
BDNF-supporting neuropeptide.
-
DIHEXA
Neurotrophic synaptogenic peptide.
-
DSIP
The glymphatic system clears beta-amyloid and metabolic waste during deep sleep; impaired slow-wave sleep is a direct risk factor for Alzheimer's, and is frequently disrupted by perimenopausal vasomotor symptoms.
-
NAD+
Neurons are the most metabolically demanding cells in the body; NAD+ depletion is implicated in age-related cognitive decline.
-
Epithalon
Supports circadian rhythm regulation and the pineal axis, which is dysregulated early in Alzheimer's pathology.
Covers neurotrophic support, glymphatic clearance via sleep, mitochondrial neuronal substrate, and circadian/pineal axis — for patients with family history seeking comprehensive prevention.
-
N-Acetyl Semax
BDNF-supporting neuropeptide.
-
N-Acetyl Selank
Addresses chronic stress and HPA dysregulation that accelerate cognitive aging.
-
DIHEXA
Neurotrophic synaptogenic peptide.
-
DSIP
Slow-wave sleep for glymphatic clearance.
-
Epithalon
Pineal-derived longevity peptide.
-
Pinealonbioregulator
Supports neuronal function and CNS longevity.
-
NAD+
Mitochondrial cofactor for neuronal energy.
-
Humanin
Documented neuroprotective effects, particularly relevant for Alzheimer's prevention given direct effects on amyloid toxicity in research models.
-
Methylene Blue
Tau aggregation inhibitor with direct research support for cognitive enhancement and neuroprotection in early Alzheimer's contexts.
Contraindicated with SSRIs/SNRIs.
Covers neurotrophic and synaptic support, stress/HPA modulation, glymphatic clearance, pineal/circadian/CNS longevity, and mitochondrial neuronal substrate.
Long-COVID-Type Fatigue / Brain Fog
Foundational mitochondrial rescue, addressing the mitochondrial dysfunction now recognized as the core pathophysiology of post-viral fatigue syndromes. Both long-COVID and ME/CFS are diagnosed disproportionately more often in women.
-
NAD+
Long-COVID is associated with documented NAD+ depletion; energy substrate restoration is one of the most consistently reported symptom-improvement strategies in post-viral fatigue research.
-
MOTS-c
Improves metabolic flexibility, exercise capacity, and cellular bioenergetics, addressing mitochondrial biogenesis deficits that underlie post-viral exercise intolerance.
Directly targets the mitochondrial dysfunction at the core of long-COVID; patient typically reports improved energy and reduced post-exertional malaise within 4–6 weeks.
-
NAD+
Foundational mitochondrial cofactor.
-
MOTS-c
Mitochondrial biogenesis peptide.
-
SS-31
The most advanced mitochondrial rescue active in the catalog, specifically relevant to membrane dysfunction in post-viral mitochondrial pathology.
-
N-Acetyl Semax
Addresses the cognitive component (brain fog, processing speed) that often persists independently of fatigue in long-COVID.
-
Thymosin Alpha-1
Rebalances the dysregulated T-cell response characteristic of post-viral syndromes.
Addresses mitochondrial substrate and biogenesis, membrane stabilization, cognitive substrate, and immune rebalancing — for multi-system long-COVID presentation.
-
NAD+
Mitochondrial cofactor.
-
MOTS-c
Mitochondrial biogenesis peptide.
-
SS-31
Mitochondrial membrane stabilization.
-
Humanin
Complements MOTS-c through a parallel mitochondrial signaling pathway.
-
Methylene Blue
Bypasses dysfunctional Complex I/III in the post-viral mitochondrial dysfunction pattern.
Contraindicated with SSRIs/SNRIs. -
N-Acetyl Semax
Cognitive support.
-
Thymosin Alpha-1
Immune-modulating peptide.
-
KPV
Addresses the chronic inflammatory state implicated in post-viral persistence.
-
DSIP
Restores slow-wave sleep architecture, severely disrupted in long-COVID and central to symptom recovery.
-
Oxytocin
Addresses the autonomic dysregulation (dysautonomia, POTS-spectrum) component of long-COVID, a presentation that disproportionately affects women.
Comprehensive mitochondrial rescue across multiple pathways, plus cognitive substrate, immune rebalancing, anti-inflammatory action, sleep architecture, and autonomic restoration — for severe or persistent long-COVID, including ME/CFS-spectrum presentations.
Suspected Mold / Heavy Metal Toxicity / Chronic Lyme
Foundational detoxification and antimicrobial support, addressing the two core pillars of chronic toxicity presentations: detoxification capacity and chronic infection load. Chronic Lyme and mold-related illness presentations are reported more frequently by women across most functional medicine clinic populations.
-
Glutathione
Master antioxidant and primary phase II detoxification cofactor; supports hepatic clearance of mycotoxins, heavy metals, and chronic infection byproducts.
-
LL-37
Direct antimicrobial activity against bacteria, fungi, and biofilm-protected pathogens implicated in chronic Lyme, mold colonization, and persistent infection states.
Patient typically reports gradual improvement in fatigue, cognitive symptoms, and inflammatory markers within 6–12 weeks.
-
Glutathione
Master antioxidant and detoxification cofactor.
-
LL-37
Antimicrobial cathelicidin.
-
Livagenbioregulator
Liver tissue-specific bioregulator supporting hepatic regeneration and detoxification capacity at the cellular level, including the added detoxification burden carried during hormonal fluctuation.
-
Thymosin Alpha-1
Rebalances the chronic Th2/Th17 dysregulation characteristic of mold illness and chronic Lyme.
-
BPC-157
Supports gut mucosal barrier repair (leaky gut is universal in mold and Lyme illness), reducing systemic inflammatory load from intestinal permeability.
Covers detoxification capacity, hepatic tissue substrate, antimicrobial defense, immune rebalancing, and gut barrier repair — for documented mycotoxin exposure or CIRS.
-
Glutathione
Master antioxidant and detoxification cofactor.
-
Livagenbioregulator
Liver tissue-specific bioregulator.
-
LL-37
Antimicrobial cathelicidin.
-
Thymosin Alpha-1
Immune-modulating peptide.
-
BPC-157
Gut mucosal barrier repair.
-
KPV
Addresses the chronic inflammatory cytokine cascade characteristic of CIRS.
-
NAD+
Mold and Lyme illness produce profound mitochondrial dysfunction and NAD+ depletion.
-
SS-31
Membrane stabilization and oxidative stress reduction in the mitochondrial damage pattern characteristic of these illnesses.
Covers detoxification substrate, hepatic tissue regeneration, antimicrobial defense, immune rebalancing, gut barrier repair, anti-inflammatory action, and mitochondrial rescue — for documented complex chronic illness.